循環器ジャーナル67巻1号

2019年01月発行

特集 循環器の現場からの検証：そのエビデンスを日本で活用するには？ Ⅲ．虚血性心疾患

Dual Antiplatelet Therapyの考え方—“The Shorter, The Better.”はアジアでどこまで本当なのか？

著者： 芳川裕亮¹ 塩見紘樹¹

所属機関： ¹京都大学大学院医学研究科循環器内科学

ページ範囲：P.82 - P.85

Point
・東洋人は欧米人と比較して，虚血性イベント率が低く出血性イベント率が高い．
・虚血性・出血性イベントのリスクのバランスを考えて治療を行うことが重要である．
・過去のstudyの結果を見れば，日本人にはShort DAPTのほうが好ましい可能性が高い．

参考文献

1) Moses JW, Leon MB, Popma JJ, et al:Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003

2) Doyle B, Rihal CS, O'Sullivan CJ, et al:Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 116:2391-2398, 2007

3) Wenaweser P, Daemen J, Zwahlen M, et al:Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 52:1134-1140, 2008

4) Kimura T, Morimoto T, Nakagawa Y, et al:Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation:five-year outcome of the j-Cypher Registry. Circulation 125:584-591, 2012

5) Valgimigli M, Campo G, Monti M, et al:Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial. Circulation 125:2015-2026, 2012

6) Navarese EP, Andreotti F, Schulze V, et al:Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents:meta-analysis of randomised controlled trials. BMJ 350:h1618, 2015

7) Mauri L, Kereiakes DJ, Yeh RW, et al:Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155-2166, 2014

8) Capodanno D, Gargiulo G, Buccheri S, et al:Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation:Do Bleeding and Stent Thrombosis Weigh Similar on Mortality? J Am Coll Cardiol 66:1639-1640, 2015

9) Généreux P, Giustino G, Witzenbichler B, et al:Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol 66:1036-1045, 2015

10) Levine GN, Jeong Y-H, Goto S, et al:Expert consensus document:World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 11:597-606, 2014

11) Kimura T, Morimoto T, Nakagawa Y, et al:Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119:987-995, 2009

12) Tada T, Natsuaki M, Morimoto T, et al:Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation:landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Interv 5:381-391, 2012

13) Natsuaki M, Morimoto T, Yamamoto E, et al:One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation:ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent（STOPDAPT）trial. Cardiovasc Interv Ther 31:196-209, 2016

14) Levine GN, Bates ER:It Is Time to End the Dualistic Short Versus Long Duration of Dual Antiplatelet Therapy Debates. Circulation 135:2451-2453, 2017

15) Levine GN, Bates ER, Bittl JA, et al:2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines:An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 134:e123-155, 2016

16) Valgimigli M, Byrne RA, Costa F, et al:2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology（ESC）and of the European Association for Cardio-Thoracic Surgery（EACTS）. Eur Heart J 39:213-260, 2018

17) Yeh RW, Secemsky EA, Kereiakes DJ, et al:Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 315:1735-1749, 2016

18) Yoshikawa Y, Shiomi H, Watanabe H, et al:Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies. Circulation 137:551-562, 2018

19) Natsuaki M, Morimoto T, Yamaji K, et al:Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention:CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc 7:e008708, 2018

20) Vranckx P, Valgimigli M, Jüni P, et al:Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicentre, open-label, randomised superiority trial. Lancet 392:940-949, 2018